The role of novel antipsychotics in bipolar disorders.
Patients with bipolar disorder frequently receive antipsychotic agents during both the acute and maintenance phases of treatment. Conventional antipsychotics are effective against mania, but they may induce depressive symptoms and expose patients with bipolar disorder to increased risks of tardive dyskinesia. Recent studies have shown risperidone to be effective for acute mania, both as monotherapy and in combination with mood stabilizers; this agent has also shown efficacy as add-on maintenance therapy in open-label studies as it exhibited both antimanic and antidepressant effects. Olanzapine, another novel antipsychotic, is also effective against both manic and depressive symptoms and in the maintenance treatment as indicated by an open-label study. Data on other novel agents are more limited.
Yatham
Lakshmi N
LN
Division of Mood Disorders, University of British Columbia, Vancouver, Canada. yatham@interchange.ubc.ca
D000208:Acute Disease; D018692:Antimanic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy*; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018967:Risperidone / Q000627:therapeutic use*
D018692:Antimanic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D008094:Lithium; D006220:Haloperidol; D018967:Risperidone; D000077152:Olanzapine